China: The Key Pharmerging Market – Deciphering Major Pharma Companies' China Strategy

It has been widely recognized that a series of changes is currently underway in the global pharmaceutical industry. All world major pharma companies are currently experiencing a number of common challenges, both internally and externally. These challenges have forced them to take all necessary actions including reducing the size of their internal R&D organization to increasingly use external resources, increasingly pursuing virtual R&D model by running the internal R&D in a way more like an R&D-focused biotech company and by focusing more on managing relationship with external partners, and closing more manufacturing facilities to outsource all general manufacturing tasks. All these actions aim to make their organization more agile and adaptive and their operation more flexible and productive.

These fundamental changes will ultimately lead to evolving of new operation models across the entire value chain of drug R&D, manufacturing and marketing. As a result, all world major pharma companies will become much slimmer and more reliant on outside. They will still conduct R&D in house but only to a minimum extent. They will still perform manufacturing tasks but only those critically important. They will still focus on marketing but the marketed products are not necessarily made by themselves.

One of the series of changes currently undertaken is the shift of marketing focus of the major pharma companies. They have now become more focused on the emerging markets. Whereas among all emerging economies, their focus is more on China than any others as they are all attracted by the fastest growth trend of the Chinese pharmaceutical market. So far all world major pharma companies have had a variety of activities in the country including R&D, manufacturing, outsourcing and marketing.

The report “China: The Key Pharmerging Market – Deciphering Major Pharma Companies’ China Strategy” analyzed, both in detail and in depth, the whole spectrum of the activities of world top ten major pharma companies in the Chinese market. It revealed their investment and marketing strategies and R&D focus in China. It also surveyed the sales revenues of these major pharma companies in the Chinese market including their past growth history, current market size and future growth potential.

The report provides by far the most comprehensive review, analysis and outlook about the world major pharmaceutical companies in the Chinese market. It provides a clear insight into their motivations and strategies in the country. It is a must-read book to all organizations and professionals in the industries of pharmaceutical, biotechnology, outsourcing service and financial investment that plan to enter the Chinese market or are interested in learning how the major companies got a firm foothold in China.